Which has better earnings and valuation, RCKT or ONCY?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is RCKT or ONCY more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media prefer RCKT or ONCY?

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Oncolytics Biotech. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Rocket Pharmaceuticals' score of 0.60 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or ONCY more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media refer more to PRLD or ONCY?

In the previous week, Prelude Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Prelude Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Prelude Therapeutics' score of 0.11 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CMPX or ONCY more profitable?

Compass Therapeutics' return on equity of -38.71% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media refer more to CMPX or ONCY?

In the previous week, Compass Therapeutics had 15 more articles in the media than Oncolytics Biotech. MarketBeat recorded 17 mentions for Compass Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Compass Therapeutics' score of -0.32 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ONCY or SION?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is ONCY or SION more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Sionna Therapeutics N/A -32.94% -31.08%

Does the media favor ONCY or SION?

In the previous week, Sionna Therapeutics had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Sionna Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Sionna Therapeutics' score of 0.14 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or ONCY more profitable?

Century Therapeutics' return on equity of -49.51% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media refer more to IPSC or ONCY?

In the previous week, Century Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Century Therapeutics' score of 0.55 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncolytics Biotech (ONCY) Competitors

$0.68 +0.00 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$0.66 -0.02 (-2.39%)

As of 07:54 PM Eastern

Compare

ONCY vs. RCKT, PRLD, CMPX, SION, and IPSC

Should you buy Oncolytics Biotech stock or one of its competitors? Oncolytics Biotech's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), Prelude Therapeutics (PRLD), Compass Therapeutics (CMPX), Sionna Therapeutics (SION), and Century Therapeutics (IPSC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals' return on equity of -52.77% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

Rocket Pharmaceuticals currently has a consensus price target of $8.63, indicating a potential upside of 220.63%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 636.16%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Oncolytics Biotech. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Rocket Pharmaceuticals' score of 0.60 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rocket Pharmaceuticals beats Oncolytics Biotech on 7 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Prelude Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Prelude Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Prelude Therapeutics' score of 0.11 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Prelude Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 119.30%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 636.16%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Prelude Therapeutics' return on equity of -75.35% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

Oncolytics Biotech has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	26.23	-$99.50M	-$0.73	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oncolytics Biotech beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Compass Therapeutics presently has a consensus target price of $10.21, indicating a potential upside of 799.94%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 636.16%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oncolytics Biotech has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	240.47	-$66.49M	-$0.40	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

In the previous week, Compass Therapeutics had 15 more articles in the media than Oncolytics Biotech. MarketBeat recorded 17 mentions for Compass Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Compass Therapeutics' score of -0.32 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compass Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Compass Therapeutics' return on equity of -38.71% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

Summary

Compass Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Sionna Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Sionna Therapeutics' return on equity of -32.94% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Oncolytics Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 636.16%. Sionna Therapeutics has a consensus price target of $42.33, suggesting a potential upside of 709.43%. Given Sionna Therapeutics' higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sionna Therapeutics had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Sionna Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Sionna Therapeutics' score of 0.14 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.8% of Oncolytics Biotech shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncolytics Biotech has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Summary

Oncolytics Biotech beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Century Therapeutics' return on equity of -49.51% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	2.80	-$9.58M	-$0.93	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

In the previous week, Century Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.75 beat Century Therapeutics' score of 0.55 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 181.07%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 636.16%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Century Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Summary

Century Therapeutics beats Oncolytics Biotech on 10 of the 15 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$90.95M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.00	14.00	274.40	25.76
Price / Sales	N/A	1,342.40	639.25	86.81
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-16.98	15.46	10.52	6.34
Net Income	-$28.76M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-11.79%	-2.21%	-1.08%	-0.11%
1 Month Performance	-19.54%	-6.66%	-3.39%	-3.42%
1 Year Performance	-45.66%	30.99%	15.08%	5.46%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	2.4228 of 5 stars	$0.68 +0.4%	$5.00 +636.2%	-46.7%	$90.95M	N/A	N/A	29	News Coverage
RCKT Rocket Pharmaceuticals	2.5629 of 5 stars	$3.43 +2.4%	$8.57 +149.9%	-2.6%	$367.74M	N/A	N/A	202
PRLD Prelude Therapeutics	2.2389 of 5 stars	$4.59 flat	$7.67 +67.0%	+318.4%	$366.30M	$22.42M	N/A	79
CMPX Compass Therapeutics	2.335 of 5 stars	$1.96 -2.0%	$11.77 +500.5%	-65.4%	$360.18M	$850K	N/A	39	Trending News Analyst Downgrade
SION Sionna Therapeutics	3.789 of 5 stars	$8.26 +5.2%	$42.22 +411.2%	-79.4%	$354.92M	N/A	N/A	59	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. RCKT, PRLD, CMPX, SION, and IPSC

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Summary

How does Oncolytics Biotech compare to Prelude Therapeutics?

Summary

How does Oncolytics Biotech compare to Compass Therapeutics?

Summary

How does Oncolytics Biotech compare to Sionna Therapeutics?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. RCKT, PRLD, CMPX, SION, and IPSC

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Which has more volatility & risk, RCKT or ONCY?

Do institutionals & insiders hold more shares of RCKT or ONCY?

Is RCKT or ONCY more profitable?

Do analysts rate RCKT or ONCY?

Which has better earnings and valuation, RCKT or ONCY?

Does the media prefer RCKT or ONCY?

Summary

How does Oncolytics Biotech compare to Prelude Therapeutics?

Does the media refer more to PRLD or ONCY?

Which has more risk & volatility, PRLD or ONCY?

Do analysts recommend PRLD or ONCY?

Is PRLD or ONCY more profitable?

Which has better valuation & earnings, PRLD or ONCY?

Do insiders & institutionals hold more shares of PRLD or ONCY?

Summary

How does Oncolytics Biotech compare to Compass Therapeutics?

Do analysts prefer CMPX or ONCY?

Which has higher earnings and valuation, CMPX or ONCY?

Does the media refer more to CMPX or ONCY?

Do insiders and institutionals hold more shares of CMPX or ONCY?

Which has more volatility & risk, CMPX or ONCY?

Is CMPX or ONCY more profitable?

Summary

How does Oncolytics Biotech compare to Sionna Therapeutics?

Is ONCY or SION more profitable?

Do analysts prefer ONCY or SION?

Does the media favor ONCY or SION?

Do insiders & institutionals have more ownership in ONCY or SION?

Which has more volatility and risk, ONCY or SION?

Which has higher earnings and valuation, ONCY or SION?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Is IPSC or ONCY more profitable?

Do institutionals and insiders believe in IPSC or ONCY?

Which has preferable valuation and earnings, IPSC or ONCY?

Does the media refer more to IPSC or ONCY?

Do analysts rate IPSC or ONCY?

Which has more risk and volatility, IPSC or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools